WEST LAFAYETTE, IN, June 30, 2022Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), today announces the appointment of Lizanne Muller as Group President, RMS. In this new role, Ms. Muller will oversee Inotiv’s Research Models business units, and Teklad diet business.

Ms. Muller joined Inotiv as part of the November 2021 Envigo acquisition and, in her former role as Vice President of Services, has been instrumental in developing and implementing the Company’s site optimization planning. Key responsibilities for her new role will include:


Lizanne Muller, Group President, RMS

  • 🔸Continuing to lead the growth and development of Inotiv’s RMS business unit
  • 🔸Developing and refining the Company’s business processes and operating model to be a more efficient and dynamic RMS business unit
  • 🔸Growing and implementing plans to consistently deliver excellent client experiences across RMS sites
  • 🔸Continuing to integrate RMS sites into a single, collaborative business unit

Ms. Muller began her career in South Africa with a large, multinational supply and logistics organization and later emigrated to the UK, joining a pharmaceutical API producer and successfully set up their global supply chain network. She spent eighteen years there in a number of progressive roles, including board member and Vice President of Compliance and Governance. She joined Envigo in 2017 as President of Operations EMEA, seeing through the transition with Covance. Ms. Muller specializes in building effective cross-functional teams, designing and driving process improvement, strategic planning, and change management.

Robert Leasure, Jr., Inotiv’s President and Chief Executive Officer, commented, “I have a great deal of confidence in Lizanne’s leadership capabilities, collaboration skills, experience, and qualifications to assume this newly created executive operational role. The entire Inotiv team looks forward to working with Lizanne as we continue to refine and grow the RMS business.”

About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here:

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

Company Contact   Investor Relations
Inotiv, Inc.   The Equity Group Inc.
Beth A. Taylor, Chief Financial Officer   Devin Sullivan
(765) 497-8381   (212) 836-9608
INSIGHTS, Keep up-to-date with the latest industry thinking and scientific insights


Keep up-to-date with the latest industry thinking and scientific insights

Explore today Explore today  

More than 90 years of working together, to build a healthier and safer world  


Explore our history Explore our history  

Subscribe to updates from Inotiv

Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.

Subscribe now